MindBio Therapeutics Past Earnings Performance

Past criteria checks 0/6

MindBio Therapeutics has been growing earnings at an average annual rate of 90.3%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually.

Key information

90.3%

Earnings growth rate

92.0%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How MindBio Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:WF6 Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240010
31 Mar 241-430
31 Dec 230-430
30 Sep 230-430
30 Jun 230-430

Quality Earnings: WF6 is currently unprofitable.

Growing Profit Margin: WF6 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if WF6's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare WF6's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: WF6 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).


Return on Equity

High ROE: WF6's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies